HRT Financial’s Lexeo Therapeutics LXEO Stock Holding History

HRT Financial’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,510	Closed	-$142K	–	3664
2025 Q3	$142K	Buy	+21,510	New	+$104K	﹤0.01%	2472

Other funds holding LXEO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

HRT Financial's LXEO Position: Q4 2025 in Review

HRT Financial sold out of Lexeo Therapeutics (LXEO) in Q4 2025, closing a stake of 21,510 shares — an estimated $142K sold.

HRT Financial first reported a position in LXEO in Q3 2025 and held it in 1 quarter. The position peaked at $142K in Q3 2025. 146 funds tracked by Wall St. Rank hold LXEO as of Q4 2025.

HRT Financial reported no remaining Lexeo Therapeutics position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 21,510 Lexeo Therapeutics shares in Q4 2025, an estimated $142K.
HRT Financial first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 1 quarter.
HRT Financial's Lexeo Therapeutics position peaked at $142K in Q3 2025.
146 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.